Please assess the completion status of the following clinical trial:

Trial Title: The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* at least 18 years old male or female~* chronic lymphoid leukaemia, any Rai stage~* 25-OH-Vitamin-D3 level between 10 and 30 ng/mL~Exclusion Criteria:~* serum calcium \> 2,60 mmol/l~* 24 hour calcium urine excretion \> 0,1 mmol/kg/day~* serum phosphate \> 1,45 mmol/l~* eGFR \< 30 ml/min/1,73m2~* nephrolithiasis~* receiving parenteral vitamin-D3 in past 6 months~* activated vitamin-D3 treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): no treatment
- Cholecalcipherol (Type: ACTIVE_COMPARATOR): Treatment with 180 000 IU cholecalcipherol monthly

Based on this trial design, predict the completion outcome and termination type (if applicable).